Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5251092 | 0.86 | F10 (0.77) | F10F2 | |
| SCHEMBL5819494 | 0.85 | F10 (1.00) | F10F2 | |
| SCHEMBL5251057 | 0.84 | F10 (1.00) | F10F2 | |
| SCHEMBL8359229 | 0.81 | F10 (1.00) | F10F2 | |
| SCHEMBL6785555 | 0.81 | F10 (1.00) | F10F2 | |
| SCHEMBL6785463 | 0.79 | F10 (0.89) | F10F2 | |
| SCHEMBL14176204 | 0.78 | F10 (1.00) | F10F2 | |
| SCHEMBL6788889 | 0.78 | F10 (0.86) | F10F2 | |
| SCHEMBL5791468 | 0.78 | F10 (0.85) | F10F2 | |
| SCHEMBL14410869 | 0.75 | F10 (0.81) | F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296982-B1 | 1-(HETEROARYL-PHENYL)-CONDENSED PYRAZOL DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2007-09-19 | — | — | EP | claimed |
| US-6506771-B2 | Anticoagulants | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-14 | — | — | US | claimed |
| US-20020119986-A1 | Heteroaryl- phenyl heterobicyclic factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-29 | — | — | US | claimed |
| EP-1296982-B1 | 1-(HETEROARYL-PHENYL)-CONDENSED PYRAZOL DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2007-09-19 | — | — | EP | disclosed |
| US-6506771-B2 | Anticoagulants | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-14 | — | — | US | disclosed |
| US-20020119986-A1 | Heteroaryl- phenyl heterobicyclic factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119986-A1 | Heteroaryl- phenyl heterobicyclic factor Xa inhibitors | SERPINC1, TFPI, F12 | F10 7/4885F2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.